Charles Duncan
Stock Analyst at Cantor Fitzgerald
(3.47)
# 803
Out of 5,182 analysts
212
Total ratings
47.29%
Success rate
20.41%
Average return
Main Sectors:
Stocks Rated by Charles Duncan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMPS COMPASS Pathways | Reiterates: Overweight | n/a | $8.89 | - | 6 | Mar 28, 2025 | |
| ACAD ACADIA Pharmaceuticals | Reiterates: Overweight | $28 | $22.30 | +25.56% | 21 | Feb 27, 2025 | |
| JAZZ Jazz Pharmaceuticals | Downgrades: Neutral | $140 → $150 | $201.22 | -25.45% | 6 | Feb 26, 2025 | |
| AXSM Axsome Therapeutics | Reiterates: Overweight | $153 | $187.40 | -18.36% | 22 | Feb 19, 2025 | |
| GHRS GH Research | Initiates: Overweight | $14 | $19.60 | -28.55% | 1 | Feb 13, 2025 | |
| DRUG Bright Minds Biosciences | Initiates: Overweight | n/a | $90.24 | - | 1 | Jan 10, 2025 | |
| BHVN Biohaven | Reiterates: Overweight | n/a | $9.59 | - | 17 | Dec 17, 2024 | |
| STOK Stoke Therapeutics | Reiterates: Overweight | n/a | $33.71 | - | 7 | Dec 10, 2024 | |
| HRMY Harmony Biosciences Holdings | Maintains: Overweight | $51 → $58 | $31.05 | +86.80% | 8 | Oct 30, 2024 | |
| ALKS Alkermes | Maintains: Overweight | $48 → $43 | $33.73 | +27.48% | 5 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $61.60 | - | 7 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $10.79 | - | 15 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $155 | $128.04 | +21.06% | 9 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $19.16 | - | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $35 | $19.94 | +75.53% | 6 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $13 | $6.79 | +91.46% | 5 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.28 | - | 2 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $4.34 | - | 3 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $34 | $29.27 | +16.16% | 9 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $52 → $50 | $38.62 | +29.47% | 3 | Oct 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $5 | $7.50 | -33.33% | 1 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $1.06 | +277.36% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $58 | $54.26 | +6.89% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $1,100 | $1.59 | +69,082.39% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $80 | $6.06 | +1,220.13% | 5 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.40 | +114.29% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $16 → $11 | $3.29 | +234.35% | 2 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $9 → $12 | $6.83 | +75.70% | 2 | Nov 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $146 → $168 | $8.07 | +1,981.78% | 6 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $4.11 | +386.62% | 1 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $200 | $29.40 | +580.27% | 3 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $4 | $2.69 | +48.70% | 3 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $372 → $144 | $1.17 | +12,207.69% | 6 | Sep 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $3 → $4 | $1.53 | +161.44% | 2 | Jun 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $35 → $39 | $64.49 | -39.53% | 4 | May 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $14 → $15 | $46.22 | -67.55% | 4 | Feb 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $0.21 | - | 3 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $2.80 | +6,328.57% | 1 | Oct 9, 2017 |
COMPASS Pathways
Mar 28, 2025
Reiterates: Overweight
Price Target: n/a
Current: $8.89
Upside: -
ACADIA Pharmaceuticals
Feb 27, 2025
Reiterates: Overweight
Price Target: $28
Current: $22.30
Upside: +25.56%
Jazz Pharmaceuticals
Feb 26, 2025
Downgrades: Neutral
Price Target: $140 → $150
Current: $201.22
Upside: -25.45%
Axsome Therapeutics
Feb 19, 2025
Reiterates: Overweight
Price Target: $153
Current: $187.40
Upside: -18.36%
GH Research
Feb 13, 2025
Initiates: Overweight
Price Target: $14
Current: $19.60
Upside: -28.55%
Bright Minds Biosciences
Jan 10, 2025
Initiates: Overweight
Price Target: n/a
Current: $90.24
Upside: -
Biohaven
Dec 17, 2024
Reiterates: Overweight
Price Target: n/a
Current: $9.59
Upside: -
Stoke Therapeutics
Dec 10, 2024
Reiterates: Overweight
Price Target: n/a
Current: $33.71
Upside: -
Harmony Biosciences Holdings
Oct 30, 2024
Maintains: Overweight
Price Target: $51 → $58
Current: $31.05
Upside: +86.80%
Alkermes
Oct 25, 2024
Maintains: Overweight
Price Target: $48 → $43
Current: $33.73
Upside: +27.48%
Oct 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $61.60
Upside: -
Sep 30, 2024
Reiterates: Overweight
Price Target: n/a
Current: $10.79
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $155
Current: $128.04
Upside: +21.06%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $19.16
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $35
Current: $19.94
Upside: +75.53%
Aug 1, 2024
Maintains: Overweight
Price Target: $11 → $13
Current: $6.79
Upside: +91.46%
Jul 30, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.28
Upside: -
Jun 21, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.34
Upside: -
Mar 22, 2024
Reiterates: Overweight
Price Target: $34
Current: $29.27
Upside: +16.16%
Oct 24, 2023
Assumes: Overweight
Price Target: $52 → $50
Current: $38.62
Upside: +29.47%
Sep 22, 2023
Initiates: Overweight
Price Target: $5
Current: $7.50
Upside: -33.33%
Aug 22, 2023
Reiterates: Overweight
Price Target: $4
Current: $1.06
Upside: +277.36%
Aug 22, 2023
Reiterates: Overweight
Price Target: $58
Current: $54.26
Upside: +6.89%
Aug 22, 2023
Reiterates: Overweight
Price Target: $1,100
Current: $1.59
Upside: +69,082.39%
Aug 16, 2023
Reiterates: Overweight
Price Target: $80
Current: $6.06
Upside: +1,220.13%
Aug 14, 2023
Reiterates: Overweight
Price Target: $3
Current: $1.40
Upside: +114.29%
Dec 6, 2022
Downgrades: Neutral
Price Target: $16 → $11
Current: $3.29
Upside: +234.35%
Nov 22, 2022
Upgrades: Overweight
Price Target: $9 → $12
Current: $6.83
Upside: +75.70%
Jun 8, 2022
Maintains: Overweight
Price Target: $146 → $168
Current: $8.07
Upside: +1,981.78%
Feb 18, 2022
Initiates: Overweight
Price Target: $20
Current: $4.11
Upside: +386.62%
Feb 18, 2022
Initiates: Overweight
Price Target: $200
Current: $29.40
Upside: +580.27%
Apr 20, 2021
Downgrades: Neutral
Price Target: $8 → $4
Current: $2.69
Upside: +48.70%
Sep 28, 2020
Downgrades: Neutral
Price Target: $372 → $144
Current: $1.17
Upside: +12,207.69%
Jun 1, 2020
Maintains: Overweight
Price Target: $3 → $4
Current: $1.53
Upside: +161.44%
May 4, 2020
Reiterates: Overweight
Price Target: $35 → $39
Current: $64.49
Upside: -39.53%
Feb 21, 2020
Reiterates: Neutral
Price Target: $14 → $15
Current: $46.22
Upside: -67.55%
Nov 15, 2017
Upgrades: Overweight
Price Target: n/a
Current: $0.21
Upside: -
Oct 9, 2017
Initiates: Overweight
Price Target: $180
Current: $2.80
Upside: +6,328.57%